Cubist Systematic Strategies, LLC Lineage Cell Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $6,813 - $8,687	5,678 Added 23.2%	30,155 $45,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.5 $13,906 - $20,451	-13,634 Reduced 35.77%	24,477 $28,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $57,249 - $89,673	-50,663 Reduced 57.07%	38,111 $43,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $99,426 - $142,926	88,774 New	88,774 $140,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $107,349 - $135,850	-47,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $208,754 - $288,600	-96,200 Reduced 66.95%	47,500 $135,000
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $254,349 - $445,470	143,700 New	143,700 $338,000
Q4 2020 Feb 16, 2021	SELL	$0.95 - $1.83 $87,215 - $168,004	-91,806 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$0.75 - $1.09 $68,854 - $100,068	91,806 New	91,806 $86,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $109M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.